On December 31, 2018 Enzychem Lifesciences, a leading global biopharmaceutical company focusing on innovative new drug development for unmet medical needs, reported that it will present at Biotech Showcase 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square (Press release, Enzychem Lifesciences, DEC 31, 2018, View Source [SID1234532326]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO & Chairman, Mr. Ki Young Sohn will present at Biotech Showcase as follows:

Date: Tuesday, January 8, 2019
Time: 9:30 am PT
Room: Franciscan A (Ballroom Level)
Location: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

On December 31, 2018 Pfizer Inc. reported that it invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 8:30 a.m. Pacific Standard Time (Press release, Pfizer, DEC 31, 2018, View Source [SID1234532320]). Effective January 1, 2019, Albert Bourla will become Chief Executive Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registering for the webcast will be available at www.pfizer.com/investors beginning today.

On December 31, 2018 United Therapeutics Corporation (NASDAQ: UTHR) reported that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company’s business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California (Press release, United Therapeutics, DEC 31, 2018, View Source [SID1234532316]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation and the immediately following Q&A session will take place on Monday, January 7, 2019, at 2:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at View Source under the "Investors" tab in the "Events and Presentations" section. An archived, recorded version of the presentation and the Q&A session will be available approximately twenty-four hours after the Q&A session ends and can be accessed at the same location for 90 days. [uthr-g]

On December 31, 2018 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, reported that Mr. Eyal Barad, CEO, will be in San Francisco in January 2019 during the J.P. Morgan Healthcare Conference (Press release, Cannabics Pharmaceuticals, DEC 31, 2018, View Source [SID1234532315]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will be meeting with Investors as well as potential partners such as Pharmaceuticals and Biotech firms from Monday, January 7th to Wednesday, January 9th.

Mr. Barad will provide an overview on the company’s mission and provide insight into the path forward towards bringing a highly valuable and needed solution to cancer patients.

Cannabics Pharmaceuticals proprietary IP, alongside its drug discovery platform and AI predictive capabilities, is based on a personalized approach to treat cancer and its side effects. The company’s goals are to leverage its technology and look at new partnerships when meeting with some of these Life Sciences companies.

On December 31, 2018 Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, reported that Bob Azelby, Alder’s president and chief executive officer, will provide a business overview and update at the 37th Annual J.P. Morgan Healthcare Conference at 8:00 am PT on Tuesday, January 8, 2019 in San Francisco, CA (Press release, Alder Biopharmaceuticals, DEC 31, 2018, View Source [SID1234532314]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Both the presentation and question and answer session that follows at 8:30 am PT will be webcast live on the Events & Presentations page of the Investors section of Alder’s website at View Source, or by following the links below in your web browser. An archived replay of each webcast will be available on Alder’s website for at least 30 days after each live event concludes.

Presentation Link:View Source
Q&A Link:View Source